

Giuseppe Mazzella

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1752216/publications.pdf>

Version: 2024-02-01

93
papers

7,762
citations

94433

37
h-index

49909

87
g-index

94
all docs

94
docs citations

94
times ranked

8523
citing authors

#	ARTICLE	IF	CITATIONS
1	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. <i>Lancet</i> , The, 2019, 394, 2184-2196.	13.7	818
2	A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. <i>New England Journal of Medicine</i> , 2016, 375, 631-643.	27.0	817
3	Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. <i>Journal of Hepatology</i> , 2016, 65, 727-733.	3.7	768
4	Serum α -fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. <i>Journal of Hepatology</i> , 2001, 34, 570-575.	3.7	677
5	Sustained virological response to interferon- α is associated with improved outcome in HCV-related cirrhosis: A retrospective study. <i>Hepatology</i> , 2007, 45, 579-587.	7.3	585
6	Measurement of Spleen Stiffness to Evaluate Portal Hypertension and the Presence of Esophageal Varices in Patients With HCV-Related Cirrhosis. <i>Gastroenterology</i> , 2012, 143, 646-654.	1.3	440
7	Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. <i>Journal of Hepatology</i> , 1996, 24, 141-147.	3.7	300
8	The cyclophilin inhibitor Debio 025 combined with PEG IFN- $2a$ significantly reduces viral load in treatment-naïve hepatitis C patients. <i>Hepatology</i> , 2009, 49, 1460-1468.	7.3	208
9	Gallstone recurrence after successful oral bile acid treatment. <i>Gastroenterology</i> , 1989, 97, 726-731.	1.3	190
10	Incidence of gallstone disease in Italy: Results from a multicenter, population-based Italian study (the Tj ETQq0 0 0,rgBT /Overlock 10 Tf	3.3	151
11	Ursodeoxycholic acid vs. chenodeoxycholic acid as cholesterol gallstone-dissolving agents: A comparative randomized study. <i>Hepatology</i> , 1982, 2, 804-810.	7.3	136
12	Ursodeoxycholic acid administration in patients with cholestasis of pregnancy: Effects on primary bile acids in babies and mothers. <i>Hepatology</i> , 2001, 33, 504-508.	7.3	129
13	Spleen stiffness measurement can predict clinical complications in compensated HCV-related cirrhosis: A prospective study. <i>Journal of Hepatology</i> , 2014, 60, 1158-1164.	3.7	123
14	Gallbladder motility in cholesterol gallstone disease. <i>Gastroenterology</i> , 1990, 99, 1779-1785.	1.3	122
15	Berberine and Its Metabolites: Relationship between Physicochemical Properties and Plasma Levels after Administration to Human Subjects. <i>Journal of Natural Products</i> , 2014, 77, 766-772.	3.0	108
16	A controlled trial of human lymphoblastoid interferon in chronic hepatitis B in Italy. <i>Hepatology</i> , 1989, 10, 336-341.	7.3	96
17	Antiinflammatory Effect of Phytosterols in Experimental Murine Colitis Model: Prevention, Induction, Remission Study. <i>PLoS ONE</i> , 2014, 9, e108112.	2.5	91
18	Indocyanine green retention test as a noninvasive marker of portal hypertension and esophageal varices in compensated liver cirrhosis. <i>Hepatology</i> , 2014, 59, 643-650.	7.3	91

#	ARTICLE	IF	CITATIONS
19	Clinical manifestations of gallstone disease: Evidence from the multicenter Italian study on cholelithiasis (MICOL). <i>Hepatology</i> , 1999, 30, 839-846.	7.3	84
20	Bile acid malabsorption and bile acid diarrhea in intestinal resection. <i>Digestive Diseases and Sciences</i> , 1982, 27, 495-502.	2.3	82
21	Hepatocellular carcinoma prevention: A worldwide emergence between the opulence of developed countries and the economic constraints of developing nations. <i>World Journal of Gastroenterology</i> , 2006, 12, 7239.	3.3	74
22	Long-Term Results With Interferon Therapy in Chronic Type B Hepatitis: A Prospective Randomized Trial. <i>American Journal of Gastroenterology</i> , 1999, 94, 2246-2250.	0.4	72
23	Adverse effects of proton pump inhibitors. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2010, 24, 193-201.	2.4	72
24	The Pharmacological Management of Intrahepatic Cholestasis of Pregnancy. <i>Current Clinical Pharmacology</i> , 2011, 6, 12-17.	0.6	70
25	Proton pump inhibitors in cirrhosis: Tradition or evidence based practice?. <i>World Journal of Gastroenterology</i> , 2008, 14, 2980.	3.3	64
26	Pneumatosis cystoides intestinalis. <i>World Journal of Gastroenterology</i> , 2011, 17, 4932.	3.3	64
27	Imaging features of microvascular invasion in hepatocellular carcinoma developed after direct-acting antiviral therapy in HCV-related cirrhosis. <i>European Radiology</i> , 2018, 28, 506-513.	4.5	63
28	A novel spleenâ€dedicated stiffness measurement by FibroScanÂ® improves the screening of highâ€risk oesophageal varices. <i>Liver International</i> , 2020, 40, 175-185.	3.9	60
29	Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals. <i>Digestive and Liver Disease</i> , 2018, 50, 573-579.	0.9	56
30	Clinical Efficacy and Effectiveness of Ursodeoxycholic Acid in Cholestatic Liver Diseases. <i>Current Clinical Pharmacology</i> , 2007, 2, 155-177.	0.6	49
31	Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals. <i>Digestive and Liver Disease</i> , 2019, 51, 681-688.	0.9	49
32	Noninvasive Assessment of Portal Hypertension in Advanced Chronic Liver Disease: An Update. <i>Gastroenterology Research and Practice</i> , 2018, 2018, 1-11.	1.5	46
33	Management of Hepatic Encephalopathy: Focus on Antibiotic Therapy. <i>Digestion</i> , 2006, 73, 94-101.	2.3	45
34	Effect of simvastatin, ursodeoxycholic acid and simvastatin plus ursodeoxycholic acid on biliary lipid secretion and cholic acid kinetics in nonfamilial hypercholesterolemia. <i>Hepatology</i> , 1992, 15, 1072-1078.	7.3	41
35	Ursodeoxycholic acid administration on bile acid metabolism in patients with early stages of primary biliary cirrhosis. <i>Digestive Diseases and Sciences</i> , 1993, 38, 896-902.	2.3	40
36	Effect of ursodeoxycholic acid administration on biliary lipid composition and bile acid kinetics in cholesterol gallstone patients. <i>Digestive Diseases and Sciences</i> , 1979, 24, 123-128.	2.3	39

#	ARTICLE	IF	CITATIONS
37	Interferon plus ribavirin and interferon alone in preventing hepatocellular carcinoma: A prospective study on patients with HCV related cirrhosis. <i>World Journal of Gastroenterology</i> , 2004, 10, 3099.	3.3	38
38	Management of intrahepatic cholestasis in pregnancy. <i>Lancet, The</i> , 1991, 338, 1594-1595.	13.7	37
39	Effect of rifaximin and paromomycin in the treatment of portal-systemic encephalopathy. <i>Current Therapeutic Research</i> , 1992, 52, 34-39.	1.2	35
40	AISF position paper on liver disease and pregnancy. <i>Digestive and Liver Disease</i> , 2016, 48, 120-137.	0.9	32
41	Lamivudine treatment for severe acute HBV hepatitis. <i>International Journal of Medical Sciences</i> , 2008, 5, 309-312.	2.5	31
42	Severe acute autoimmune hepatitis after natalizumab treatment. <i>Digestive and Liver Disease</i> , 2012, 44, 356-357.	0.9	31
43	Curcuma longa Extract Exerts a Myorelaxant Effect on the Ileum and Colon in a Mouse Experimental Colitis Model, Independent of the Anti-Inflammatory Effect. <i>PLoS ONE</i> , 2012, 7, e44650.	2.5	30
44	Relationship between indocyanine green retention test, decompensation and survival in patients with Child-Pugh A cirrhosis and portal hypertension. <i>Liver International</i> , 2016, 36, 1313-1321.	3.9	29
45	Gastric autoimmune disorders in patients with chronic hepatitis C before, during and after interferon-alpha therapy. <i>World Journal of Gastroenterology</i> , 2003, 9, 1487.	3.3	29
46	Comparative evaluation of chenodeoxycholic and ursodeoxycholic acids in obese patients. <i>Gastroenterology</i> , 1991, 101, 490-496.	1.3	28
47	A randomized trial of consensus interferon in combination with ribavirin as initial treatment for chronic hepatitis C. <i>Journal of Hepatology</i> , 2003, 39, 843-849.	3.7	28
48	Sluggish Small Bowel Motility Is Involved in Determining Increased Biliary Deoxycholic Acid in Cholesterol Gallstone Patients. <i>American Journal of Gastroenterology</i> , 1999, 94, 2453-2459.	0.4	25
49	Is It Possible to Predict the Clinical Course of Gallstone Disease? Usefulness of Gallbladder Motility Evaluation in a Clinical Setting. <i>American Journal of Gastroenterology</i> , 2006, 101, 2576-2581.	0.4	25
50	Identification of naïve HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin. <i>Journal of Hepatology</i> , 2014, 60, 16-21.	3.7	25
51	Spleen stiffness mirrors changes in portal hypertension after successful interferon-free therapy in chronic-hepatitis C virus patients. <i>World Journal of Hepatology</i> , 2018, 10, 731-742.	2.0	24
52	Ribavirin for chronic hepatitis C: And the mystery goes on. <i>Digestive and Liver Disease</i> , 2011, 43, 425-430.	0.9	22
53	Size and location of spontaneous portosystemic shunts predict the risk of decompensation in cirrhotic patients. <i>Digestive and Liver Disease</i> , 2022, 54, 103-110.	0.9	22
54	Long-term alpha interferon and lamivudine combination therapy in non-responder patients with anti-HBe-positive chronic hepatitis B: Results of an open, controlled trial. <i>World Journal of Gastroenterology</i> , 2003, 9, 1491.	3.3	21

#	ARTICLE	IF	CITATIONS
55	Systemic fungemia and hepatic localizations of <i>Fusarium solani</i> in a liver transplanted patient: An emerging fungal agent. <i>Liver Transplantation</i> , 2006, 12, 1711-1714.	2.4	20
56	AISF position paper on liver transplantation and pregnancy. <i>Digestive and Liver Disease</i> , 2016, 48, 860-868.	0.9	20
57	Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Therapy with Direct-Acting Antivirals. A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 1694.	2.4	20
58	Transjugular intrahepatic portosystemic shunt placement for refractory ascites: a single-centre experience. <i>Scandinavian Journal of Gastroenterology</i> , 2012, 47, 1494-1500.	1.5	19
59	Efficacy of ursodeoxycholic acid in association with $\hat{1}\pm$ -interferon for chronic hepatitis C in $\hat{1}\pm$ -interferon non-responder patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2000, 12, 511-516.	1.6	17
60	Lack of Correlation Between Serum Anti-HBcore Detectability and Hepatocellular Carcinoma in Patients With HCV-Related Cirrhosis. <i>American Journal of Gastroenterology</i> , 2008, 103, 1966-1972.	0.4	17
61	Extracorporeal shock wave lithotripsy for difficult common bile duct stones: a comparison between 2 different lithotripters in a large cohort of patients. <i>Gastrointestinal Endoscopy</i> , 2015, 81, 402-409.	1.0	17
62	Fatty liver in pregnancy: a narrative review of two distinct conditions. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020, 14, 127-135.	3.0	17
63	ESWL for difficult bile duct stones: A 15-year single centre experience. <i>World Journal of Gastroenterology</i> , 2010, 16, 4159.	3.3	17
64	Prognostic Value of the Albumin-Bilirubin Grade for the Prediction of Post-Hepatectomy Liver Failure: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 2011.	2.4	16
65	Systemic lupus erythematosus following virological response to peginterferon alfa-2b in a transplanted patient with chronic hepatitis C recurrence. <i>World Journal of Gastroenterology</i> , 2006, 12, 4253.	3.3	15
66	Spleen Stiffness Measurements Predict the Risk of Hepatic Decompensation After Direct-Acting Antivirals in HCV Cirrhotic Patients. <i>Ultraschall in Der Medizin</i> , 2020, , .	1.5	15
67	Curcuma longa L. as a Therapeutic Agent in Intestinal Motility Disorders. 2: Safety Profile in Mouse. <i>PLoS ONE</i> , 2013, 8, e80925.	2.5	13
68	G-CSF in Peg-IFN induced neutropenia in liver transplanted patients with HCV recurrence. <i>World Journal of Gastroenterology</i> , 2009, 15, 5449.	3.3	12
69	High Doses of Ursodeoxycholic Acid Up-Regulate the Expression of Placental Breast Cancer Resistance Protein in Patients Affected by Intrahepatic Cholestasis of Pregnancy. <i>PLoS ONE</i> , 2013, 8, e64101.	2.5	12
70	Interleukin 28 Polymorphisms and Hepatocellular Carcinoma Development after Direct Acting Antiviral Therapy for Chronic Hepatitis C. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019, 28, 449-456.	0.9	10
71	Methylprednisolone administration in primary biliary cirrhosis increases cholic acid turnover, synthesis, and deoxycholate concentration in bile. <i>Digestive Diseases and Sciences</i> , 1999, 44, 2478-2483.	2.3	8
72	A New Model for Portal Protein Profile Analysis in Course of Ileal Intraluminal Bile Acid Infusion Using an In Situ Perfused Rat Intestine. <i>Medicinal Chemistry</i> , 2011, 7, 257-264.	1.5	8

#	ARTICLE	IF	CITATIONS
73	An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C. <i>Digestive and Liver Disease</i> , 2014, 46, 818-825.	0.9	8
74	Imbalance of Neutrophils and Lymphocyte Counts Can Be Predictive of Hepatocellular Carcinoma Occurrence in Hepatitis C-related Cirrhosis Treated With Direct-acting Antivirals. <i>Gastroenterology</i> , 2018, 154, 2281-2282.	1.3	7
75	The UDCA dosage deficit: a fate shared with CDCA. <i>European Journal of Gastroenterology and Hepatology</i> , 2002, 14, 213-216.	1.6	5
76	Persistent Fever and Abdominal Pain in a Young Woman With Budd-Chiari Syndrome. <i>Gastroenterology</i> , 2018, 154, 495-497.	1.3	5
77	The impact of assisted reproductive technology and chorionicity in twin pregnancies complicated by obstetric cholestasis. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2016, 29, 1481-1484.	1.5	4
78	Consensus interferon (CIFN) in combination with ribavirin (RBV) for naïve patients with chronic hepatitis C: a multicenter study. <i>Journal of Hepatology</i> , 2002, 36, 234.	3.7	3
79	Noninvasive diagnosis of portal hypertension and esophageal varices through the identification of liver blood flow markers. <i>Hepatology</i> , 2014, 60, 762-762.	7.3	3
80	Long-term leukocyte natural killer-interferon and ribavirin treatment in hepatitis C virus recurrence after liver transplantation. <i>World Journal of Gastroenterology</i> , 2013, 19, 5278.	3.3	3
81	Severe immune thrombocytopenia after peg-interferon-alpha2a, ribavirin and telaprevir treatment completion: A case report and systematic review of literature. <i>World Journal of Hepatology</i> , 2015, 7, 1718.	2.0	3
82	High Dose Lamivudine in HBV-Related Cirrhotic Patients with Unsatisfactory Response After Adefovir Add-On. <i>Digestive Diseases and Sciences</i> , 2012, 57, 561-567.	2.3	2
83	Correlation between Indocyanine green retention test and esophageal varices among patients with hepatocellular carcinoma. <i>Journal of Gastroenterology</i> , 2014, 49, 954-955.	5.1	2
84	An unusual cause of weight loss in a young Caucasian man. <i>Gut</i> , 2014, 63, 856.1-856.	12.1	2
85	Ductal stones recurrence after extracorporeal shock wave lithotripsy for difficult common bile duct stones: Predictive factors. <i>Digestive and Liver Disease</i> , 2017, 49, 1128-1132.	0.9	2
86	A multimedia multilanguage web-based platform can assess and increase the awareness on HCV infection of Pakistani people living in Italy. <i>Journal of Viral Hepatitis</i> , 2021, 28, 764-770.	2.0	2
87	Complete Remission of Advanced Hepatocellular Carcinoma Treated with Sorafenib and Concomitant Appearance of IgG4-related Diseases. A Case Report. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 30, 142-146.	0.9	2
88	Indocyanine Green Clearance as a Marker of Decompensation and Clinically Significant Portal Hypertension in Patients With Liver Cirrhosis. <i>Gastroenterology</i> , 2011, 140, S-958.	1.3	1
89	Alisporivir for the treatment of chronic HCV. <i>Future Virology</i> , 2012, 7, 9-18.	1.8	1
90	Telbivudine treatment for fulminant HBV hepatitis. <i>Journal of Digestive Diseases</i> , 2013, 14, n/a-n/a.	1.5	1

#	ARTICLE	IF	CITATIONS
91	The future of dual therapy for hepatitis C virus. Future Virology, 2014, 9, 905-912.	1.8	1
92	Reply. Hepatology, 2015, 61, 2113-2114.	7.3	0
93	Effects of Combined IFN-Alpha/Ribavirin Treatment in HCV Disease-Related Progression. , 2008, , 215-236.		0